Inhibitory Effect of Ginsenoside Rg1 on Vascular Smooth Muscle Cell Proliferation Induced by PDGF-BB Is Involved in Nitric Oxide Formation by Huang, Jing et al.
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 314395, 7 pages
doi:10.1155/2012/314395
Research Article
Inhibitory Effectof Ginsenoside Rg1 on
Vascular Smooth Muscle Cell Proliferation Inducedby
PDGF-BB Is Involved in Nitric Oxide Formation
Jing Huang,1,2 Li-Sheng Li,1 Dan-LiYang,1 Qi-HaiGong,1
Jiang Deng,1 andXie-Nan Huang1
1Department of Pharmacology of Zunyi Medical College and the Key Laboratory of Basic Pharmacology of Guizhou,
Zunyi 563003, China
2Department of Pharmacology, Mindong Medical School, 65 Manchun Road, Fujian, Fuan, 355017, China
Correspondence should be addressed to Xie-Nan Huang, huangxienan@yahoo.com.cn
Received 12 October 2011; Accepted 17 December 2011
Academic Editor: Youn Chul Kim
Copyright © 2012 Jing Huang et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
GinsenosideRg1(Rg1)hasbeenreportedtosuppresstheproliferationofvascularsmoothmusclecells(VSMCs).Thisstudyaimed
to observe the role of nitric oxide (NO) in Rg1-antiproliferative eﬀect. VSMCs from the thoracic aorta of SD rats were cultured
by tissue explant method , and the eﬀe c to fR g 1( 2 0m g·L−1,6 0m g·L−1, and 180mg·L−1) on platelet-derived growth factor-BB
(PDGF-BB)-induced proliferation was evaluated by MTT assay. The cell cycle was analyzed by ﬂow cytometry. For probing the
mechanisms, the content of NO in supernatant and cGMP level in VSMCs was measured by nitric oxide kit and cGMP radio-
immunity kit, respectively; the expressions of protooncogene c-fos and endothelial NO synthase (eNOS) mRNA in the VSMCs
were detected by real-time RT-PCR; the intracellular free calcium concentration ([Ca2+]i) was detected with Fura-2/AM-loaded
VSMCs. Comparing with that in normal group, Rg1 180mg·L−1 did not change the absorbance of MTT and cell percent of
G0/G1,G 2/M, and S phase in normal cells (P>0.05). Contrarily, PDGF-BB could increase the absorbance of MTT (P<0.01)
and the percent of the S phase cells but decrease the G0/G1 phase cell percent in the cell cycle, accompanied with an upregulating
c-fos mRNA expression (P<0.01), which was reversed by additions of Rg1(20mg·L−1,6 0m g ·L−1, and 180mg·L−1). Rg1
administration could also signiﬁcantly increase the NO content in supernatant and the cGMP level in VSMCs, as well as the
eNOS mRNA expression in the cells, in comparison of that in the group treated with PDGF-BB alone (P<0.01). Furthermore,
Rg1 caused a further increase in the elevated [Ca2+]i induced by PDGF-BB. It was concluded that Rg1 could inhibit the VSMC
proliferation induced by PDGF-BB through restricting the G0/G1 phase to S-phase progression in cell cycle. The mechanisms may
be related to the upregulation of eNOS mRNA and the increase of the formation of NO and cGMP.
1.Introduction
Ginsenoside Rg1 (Rg1) is believed to be one of the main
active principles in ginseng (Panax ginseng C. A. Meyer),
a traditional Chinese medicine used to enhance stamina
and capacity to cope with fatigue as well as physical stress.
It has been reported that Rg1 has many beneﬁcial eﬀects
on several systems. For example, in cardiovascular system,
Rg1 can ameliorate the ventricular remodeling induced by
myocardial infarction [1] and the left ventricular hyper-
trophy induced by abdominal aorta coarctation [2]i nr a t s
and protect rat cardiomyocyte from hypoxia/reoxygenation
oxidative injury [3]. Also, Rg1 has been reported to inhibit
proliferation of vascular smooth muscle cells (VSMCs)
induced by tumor necrosis factor-α and block the cell cycle
in the G1-phase via depressing the signaling pathways of
ERK, PI3K/PKB, and PKC [4, 5]. However, cell proliferation
is modulated by many factors, more studies should be done
to elucidate the action mechanisms of the antiproliferative
eﬀect of Rg1.
Nitric oxide (NO) has been known to exert many
diﬀerent vasoprotective eﬀects, such as inhibitions of platelet2 Evidence-Based Complementary and Alternative Medicine
aggregation [6], leukocyte chemotaxis [7], and endothelial
cell apoptosis [8]. For vasculature, mounting evidence has
indicated that NO can inhibit VSMC proliferation in vitro
and prevent the development of intimal hyperplasia after
vascular injury in vivo [9–11]. The inhibitory eﬀect of
S-nitroso-N-acetylpenicillamine and sodium nitroprusside,
the NO donors, on VSMC proliferation was thought via
cGMP-dependent [12] and cGMP-independent [13–15]
mechanisms. On the other hand, Rg1 has been reported to
cause endothelial-dependent relaxation in the rat aorta [16],
enhance endogenous NO production in human umbilical
vein endothelial cells [17], rat kidney [18], and in porcine
coronary arteries [19]. Interestingly, some pharmacological
eﬀects of Rg1 have been attributed to endogenous NO pro-
duction,suchasitsimprovingeﬀectonmalemicecopulatory
behavior [20] and its protection against left ventricular
hypertrophy induced by abdominal aorta coarctation in rats
[21]. However, whether the antiproliferative eﬀect of Rg1 on
VSMC involves in endogenous NO production is unknown.
This study aimed to investigate the possible inﬂuence of
Rg1 on the cell-cycle progression induced by platelet-derived
growth factor-BB (PDGF-BB) and observe the role of NO in
Rg1 antiproliferative eﬀect on VSMC.
2.MaterialsandMethods
2.1.MaterialsandAnimals. Rg1(purity>97%)wasobtained
from Beijing Naturally Occurring Drugs Research Insti-
tute, China. Other reagents and their sources were mainly
as follows: platelet-derived growth factor-BB (PDGF-BB)
(Sigma-Aldrich Co. USA); 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide(MTT),propidiumiodide(PI)
dye, and Rnase A (Beijing Solarbio Science Technology Co.
Beijing, China); Nitric oxide kit (Jiangsu Beyotime institute
of Biotechnology. Jiangsu, China); cGMP radio-immunity
kit (Beijing Puerweiye Biological Engineering Co. Beijing,
China); β-actin primer endothelial nitric oxide synthase
(eNOS) primer, c-fos primer and Cyclin D1 primer (Dalian
TakaRa Biological Engineering Co. Dalian, China).
Sprague-Dawley rats (150∼200g) were purchased from
the Animal Center of Institute of Surgery Research of the
Third Military Medical University (Chongqing, China).
2.2. Cell Culture and Experimental Design. Rat VSMCs were
isolated from rat thoracic aorta using the explanting tech-
nique [22]. Brieﬂy, the aortic pieces (about 1mm3)r e m o v e d
the endothelium, and adventitia were cultured in Dulbecco’s
modiﬁed Eagle’s medium (Invitrogen Gibco, USA) contain-
ing 20% bovine serum, penicillin 100 U/mL, streptomycin
100μg/mL at 37◦C in a humidiﬁed atmosphere of 95% air
and 5% CO2. After about 10 days, the cells were removed
by trypsinization and successively subcultured. Cells from
passages 3 to 10 were used for the experiments.
The VSMCs were randomly divided into six groups:
Normal group (Normal): no drug was added; N + Rg1 group
(N + Rg1): Rg1 180mg·L−1 was added in normal cells;
PDGF-BB model group (Model): PDGF-BB 25μg·L−1 was
added in normal grown cells; Rg1 low-dose group (Rg1-L),
middle-dose group (Rg1-M), and high-dose group (Rg1-H):
Rg1 20mg·L−1, 60mg·L−1, 180mg·L−1 were added,re-
spectively, to the cells treated with 25μg·L−1 PDGF-BB. The
aboveconcentrationsofPDGF-BBorRg1usedineachgroup
were ﬁnal concentration.
2.3. Assessment of VSMC Proliferation by MTT Assay. The rat
VSMCs were harvested by trypsinization and plated in a 96-
well plate at a density of 1 × 105 cells/mL. PDGF-BB and
Rg1 were added to each well as the mention in experimental
design (PDGF-BB was added at 30min after the addition of
Rg1). Brieﬂy, MTT assays were carried out as follow: VSMCs
were grown in 100μLm e d i u ma t3 7 ◦C under 5% CO2 for
24h in 96-well plates, followed by a incubation with 10μL
MTT (5g·L−1) for 4h. Then 100μL (dimethyl sulfoxide)
DMSOwereaddedtoeachwell,andanabsorbanceat490nm
was read on a Microplate reader.
2.4. Cell-Cycle Analysis Using Flow Cytometry (FCM).
VSMCs were seeded in six-well plastic culture dishes at a
density of 5×105 cells/mL, PDGF-BB and Rg1 were added as
MTT assay after cell synchronization and cultured for 24h.
Thereafter, VSMCs were harvested by trypsinization and
collected from the six-well plate, placed in Eppendorf tubes
a n dw a s h e dw i t h4 ◦C PBS twice, then ﬁxed with 2mL 70%
ice-ethanol overnight. After centrifugalization, the VSMCs
werewashedwithPBStwiceagain.Finally,theDNAcontents
of VSMCs were determined by PI staining and FCM analysis.
2.5. Real-Time RT-PCR Analysis of c-Fos, and eNOS mRNA.
VSMCs were seeded in 25mL culture ﬂask at a density of
1×105 cells/ﬂask, total RNA was isolated by using the TRIzol
(MRC Co., Cincinnati, USA) method after 24h of PDGF-BB
and Rg1 action. Two-step reverse-transcription polymerase
chain reaction was used to detect the expression by iCycle iQ
Real-TimePCRDetectionSystem(BIO-RADCo.,California,
USA), with SYBR Green PCR Master Mix (ABI Co., Foster,
USA). The Primers were designed with Express Software
and synthesized by TaKaRa Biological Engineering Company
(Dalian, China). The following Primers were used: c-fos
(GenBankaccessionno.RA 011723):forwardprimer(5 –3 )
CCC GGC ATC CTT ATT CAA TTA TCA, reverse primer
(5 –3 ) GTG TTA TCC CAC AGC ATG TCA ACA G; eNOS
(GenBank accession no. NM 021838): forward primer (5 –
3 ) AGC TGG ATG AAG CCG GTG AC, reverse primer (5 –
3 ) CCT CGT GGT AGC GTT GCT GA; β-actin (GenBank
accession no. NM 031144): forward primer (5 –3 )GGC
CAA CCG TGA AAA GAT GA, reverse primer (5 –3 )C A G
CCT GGA TGG CTA CGT ACA. The reaction conditions
were 95◦C1 0m i n1c y c l e ;9 5 ◦C 15s, annealing temperature
1min, 40 cycles. The threshold cycle (Ct) values of target
genes were normalized with β-actin of the same sample, and
expressed as were relative to controls.
2.6. Measurements of NO Content in Supernatant and cGMP
Level in VSMCs. The measurements of NO content in
supernatant and cGMP level in VSMCs were undertaken
accordingtothemanufacturer’sinstructionsintheassaykits.
VSMC culture cell synchronization and experimental design
were in accordance with MTT assay.Evidence-Based Complementary and Alternative Medicine 3
2.7. Measurement of the Intracellular Free Calcium Con-
centration ([Ca2+]i) in VSMCs. The cultured VSMCs were
centrifuged at 150g for 5min at room temperature.The
supernatant was discarded, and the cells were washed twice
with Hanks solution (in mmol/L:NaCl 137.0, CaCl2 1.3,
KCl 5.4, MgSO4 0.8, NaHPO4 0.38, KH2PO4 0.44, NaHCO3
4.2, sucrose 5.6, BSA 0.2%; pH 7.4), then the cells were
incubated in Hanks solution containing 3μmol/L Fura-
2/AM for 40min at 37◦C, followed by washing twiced to
remove the extracellular dye. Finally, the cell number was
adjusted to 1 ×10
−6 cells/mL for measurement of [Ca2+)]i.
The ﬂuorescence value from 1mL cell suspension was
measured by a RF-5000 dual-wavelength spectroﬂuorometer
(Shimadzu Company, Japan) with excitation wavelengths
at 340/380nm and emission wavelength at 480nm. The
ratio (R) of the ﬂuorescence signals at 340/380 (nm) was
calculated automatically, and the maximal R value (Rmax)
and minimal R value (Rmin) were determined by the addition
of 10μL 10% TritonX-100 (ﬁnal concentration 0.1%) and
10μL 500mmol/L EGTA (ﬁnal concentration 5mmol/L),
respectively. The [Ca2+]i was calculated by the formula
described before [22][ C a 2+)]i = 224 × [(R − Rmin)/(Rmax −
R)] × FD/FS,w h e r eFD and FS are the ﬂuorescence
proportionality coeﬃcients obtained at 380nm under Rmin
and Rmax conditions, respectively. The number 224 is the
KD value of Fura-2/AM. To observe the possible inﬂuence
of Rg1 on the elevated [Ca2+)]i induced by PDGF-BB, Rg1
was added before the addition of this growth factor, and the
ﬂuorescence intensity was detected at 5min after PDGF-BB
addition.
2.8. Statistical Analysis. All data are presented as mean ±
S.E.M. and were analyzed by the one-way ANOVA followed
by Student’s t-test (two-tails) with the SPSS 13.0 software
(SPSS Inc, Chicago, Illinois, USA), and signiﬁcance was set
at P<0.05.
3. Results
3.1. Eﬀect of Rg1 on MTT Assay in Rat VSMCs. In normal
cells without any treatment of growth factor, Rg1 180mg ·L−1
did not change the MTT absorbance, while the addition
of PDGF-BB could signiﬁcantly increase the absorbance in
MTT assay (P<0.01), which tended to be inhibited by an
addition of Rg1 20mg·L−1 (P>0.05), and was remarkably
inhibited by Rg1 60mg·L−1and 180mg·L−1 (P<0.05 and
P<0.01), suggesting the antiproliferating eﬀect of Rg1 on
VSMCs (Figure 1).
3.2. Eﬀect of Rg1 on the Cell Cycle Induced by PDGF-BB in Rat
VSMCs. The results shown in Figure 2 demonstrated that
Rg1 180mg·L−1 had no any eﬀect on the growth of normal
cells, while PDGF-BB could signiﬁcantly increase the percent
of S-phase cells and degrade the G0/G1-phase cell percent in
the cell cycle (P<0.01) administration of Rg1 (20mg·L−1,
60mg·L−1,180mg·L−1)at30minafterPDGF-BBaddition
could markedly decrease the S-phase cell percent and
upgrade the G0/G1 phase percent in the cell cycle. The data
suggested that Rg1 could inhibit the VSMC proliferation
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Figure 1: Effect of Rg1 on PDGF-BB-induced VSMC proliferation
(MTT assay, x ± s, n = 7). The VSMCs were cultured for
24h. Normal: vehicle; N+Rg1: Rg1 180mg·L−1;m o d e l :P D G F -
BB 25μg·L−1;R g 1 - L :R g 12 0 m g ·L−1 +P D G F - B B2 5 μg·L−1;
Rg1-M: Rg1 60mg·L−1 +PDGF-BB 25μg·L−1; Rg1-H: Rg1
180mg·L−1 +P D G F - B B 2 5μg·L−1. Data were mean ± S.E.M.
##SigniﬁcantdiﬀerencefromnormalcontrolatP<0.01∗ signiﬁcant
diﬀerence from model control at P<0.05, and ∗∗ signiﬁcant
diﬀerence from model control at P<0.01.
induced by PDGF-BB through restricting the G0/G1-phase
to S-phase progression in cell cycle.
3.3. Eﬀect of Rg1 on the Expression of c-Fos and eNOS mRNA.
The results from real-time RT-PCR assay indicated that
PDGF-BB could elevate the c-fos mRNA expression by about
10 times of that in the normal control, and Rg1 could
signiﬁcantly blunt the c-fos expression (P<0.01). On the
other hand, addition of PDGF-BB decreased the expression
of eNOS mRNA by about 67%, and Rg1 could reverse the
decreasing eNOS expression in a concentration-dependent
manner (P<0.01) (Figure 3).
3.4. Changes of NO Content in Supernatant and cGMP
Level in VSMCs. As shown in Figure 4(a),P D G F - B Bc o u l d
signiﬁcantly degrade the content of NO in the supernatant
of the cultured VSMCs (P<0.01), the addition of the low
concentration of Rg1 (20mg·L−1) tended to increase the
NO content (P>0.05), and the higher concentrations of
Rg1 (60mg·L−1, 180mg·L−1) could signiﬁcantly elevate
the content of NO (P<0.05 or P<0.01). Consistent with
the changes of NO content in supernatant, the cGMP level in
VSMCs was also decreased by PDGF-BB (P<0.01) and was
markedly increased by additions of all three concentrations
of Rg1 (P<0.05 or P<0.01) (Figure 4(b)).
3.5. Change of [Ca2+]i in VSMCs by Rg1 treatment. The
[Ca2+]i levels of VSMCs were detected at 3 minutes after
the addition of PDGF-BB or at 33 minutes after Rg1-
administration. In our experimental conditions, the basal
[Ca2+]i was about 120nmol/L in normal VSMCs; it tended
to increase by Rg1 180mg·L−1 (P>0.05), and was elevated
to 182nmol/L by the addition of PDGF-BB 25μg·L−1(P<
0.05). When Rg1 was administered at 30 minutes before
PDGF-BB addition, it could cause a further increase in the
elevated [Ca2+]i induced by this growth factor in a dose-
dependent manner (Figure 5).4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Eﬀe c to fR g 1o nt h eV S M Cc e l lc y c l ei nt h ep r e s e n c eo fP D G F - B B( x ± s, n = 4 ∼ 6,%). A: representative results of ﬂow
cytometry measurements to determine the cell-cycle stages of VSMCs; B:percentage of cells in each phase of the cell cycle. Normal: vehicle;
N+Rg1: Rg1 180mg·L−1;m o d e l:P D G F - B B2 5μg·L−1; Rg1-L:Rg1 20mg·L−1 +P DG F - B B2 5μg·L−1; Rg1-M:Rg1 60mg·L−1 +PDGF-
BB 25μg·L−1; Rg1-H:Rg1 180mg·L−1 +PDGF-BB 25μg·L−1.Data were mean ± S.E.M. ##Signiﬁcant diﬀerence from normal control at
P<0.01; ∗∗ signiﬁcant diﬀerence from model control at P<0.01.Evidence-Based Complementary and Alternative Medicine 5
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Figure 3: Eﬀe c t so fR g 1o nt h ec h a n g e so fe x p r e s s i o n so fc - f o sa n d
eNOS mRNA induced by PDGF-BB in VSMC (x ± s,n = 3); real-
time RT-PCR analysis of c-fos, and eNOS mRNA were performed
after24hofPDGF-BBandRg1actionsinVSMCs.Normal:vehicle;
model:PDGF-BB 25μg·L−1; Rg1-L:Rg1 20mg·L−1 +P D G F - B B
25μg·L−1; Rg1-M:Rg1 60mg·L−1 +PDGF-BB 25μg·L−1;R g 1 -
H:Rg1 180mg·L−1 +PDGF-BB 25μg·L−1. Data were mean ±
S.E.M. ##Signiﬁcant diﬀerence from normal control at P<0.01; ∗∗
signiﬁcant diﬀerence from model control at P<0.01.
4. Discussion
VSMC proliferation has been known to be an impor-
tant component of vessel wall remodelling in response to
injury, such as after angioplasty and during atherosclerosis
formation [23, 24]. The development of highly eﬀective
antiproliferative drugs is necessary for the prevention and
treatment of hypertrophic vascular diseases. Rg1 has been
reported to inhibit TNF-α-induced human arterial smooth
muscle-cell proliferation and cause cell-cycle arrest in G1
phase [4], and PDGF-BB is known to be a mitogen
involved in the development of vascular proliferative lesions
observedinatherosclerosisandinrestenosisafterangioplasty
[25, 26]. In the present study, we further certiﬁed the
antiproliferative eﬀect of Rg1 on the VSMCs from rat-
thoracic aorta, using PDGF-BB to induce cell proliferation.
Our study also certiﬁed that Rg1 could cause G0/G1 cell
cycle arrest in rat VSMCs, which was very consistent with
the report [4]. Furthermore, VSMC proliferation has been
known to be promoted by the concerted action of several
distinct signal transduction pathways, such as phospholipase
C isoforms and mitogen-activated protein kinase (MAPK)
cascade [27–29]. The ﬁnal result of these pathways activation
is transcription and activation of the early response genes c-
fos and c-jun. Rg1 has been reported to inhibit the PKC and
MAPK signalings in TNF-α-treated human arterial smooth
muscle cells [4, 5]; in this study, we found that Rg1 could
also signiﬁcantly inhibit the elevated c-fos mRNA expression
induced by PDGF-BB, which might be the result of the
transduction pathway inhibitions.
Because NO has been shown to play diverse roles in
the physiology and pathophysiology of the cardiovascular
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Figure 4: Effects of Rg1 on the NO content in supernatant (a) and
cGMP level in cultured VSMCs (b) in the presence of PDGF-BB.
VSMCs were cultured for 24h, the NO content in supernatant and
cGMP level in the cells were determined with the corre- sponding
Kits. Normal: vehicle; model: PDGF-BB 25μg·L−1; Rg1-L:Rg1
20mg·L−1 +P D G F - B B2 5 μg·L−1; Rg1-M:Rg1 60mg·L−1 +
PDGF-BB 25μg·L−1; Rg1-H:Rg1 180mg·L−1 +P D G F - B B
25μg·L−1. Data were mean ± S.E.M. ##Signiﬁcant diﬀerence from
normal control at P<0.01; ∗∗ signiﬁcant diﬀerence from model
control at P<0.01.
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Figure 5: Eﬀect of Rg1 on the intracellular free Ca2+ concen-
tration ([Ca2+]i) of VSMCs. The [Ca2+]i was detected after 3
minutes of PDGF-BB addition with Fura-2/AM loaded VSMCs,
and Rg1 administrations were performed before 30 minutes
of the addition of PDGF-BB. Normal:vehicle; model:PDGF-
BB 25μg·L−1; Rg1-L:Rg1 20mg·L−1 +P D G F - B B2 5 μg·L−1;
Rg1-M:Rg1 60mg·L−1 +P D G F - B B2 5 μg·L−1; Rg1-H:Rg1
180mg·L−1 +P D G F - B B 2 5μg·L−1. Data were mean ± S.E.M.
#SigniﬁcantdiﬀerencefromnormalcontrolatP<0.05; ∗signiﬁcant
diﬀerence from model control at P<0.05, ∗∗Signiﬁcant diﬀerence
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system, including inhibition of VSMC proliferation [9],
and Rg1 has been known to promote the endogenous NO
production in many tissues [16–21], in the present study, we
have emphatically observed the inﬂuences of Rg1 on the NO
content in supernatant, cGMP level and [Ca2+]i in VSMCs,
as well as the expression of eNOS in the cells, to clarify the
relationship between the antiproliferative eﬀect of Rg1 and
NO formation.
It is known that NO stimulates cytosolic soluble guanylyl
cyclase to increase cGMP formation, which accompany the
activation of cGMP-dependent protein kinase [30, 31]and it
has also been known that the NO donors, such as S-nitroso-
N-acetylpenicillamine (SNAP) and sodium nitroprusside,
inhibit VSMC proliferation by cGMP-dependent [12]a n d
cGMP-independent [13–15] mechanisms. In our study, we
found that both NO content in supernatant and cGMP level
in VSMCs were degraded by addition of PDGF-BB and
elevated by Rg1-treatment. The results seemed to suggest
that the increase in cGMP level was from the NO formation
after Rg1 addition. Consistent with above results, we also
found that Rg1 could signiﬁcantly upregulate the expression
of eNOS in VSMCs in a concentration-dependent manner.
Taking the above results together, it appears to be possible
that Rg1 promotes the NO formation through upregulating
the NOS (at least for eNOS) expression, and to stimulate
cytosolic soluble guanylyl cyclase to increase cGMP forma-
tion, then the NO itself and cGMP participate the inhibition
on VSMC proliferation. It has been reported that in human
umbilical vein endothelial cells, Rg1 can downregulate miR-
214 (a microRNA related closely to eNOS) expression,
leading to an increase in eNOS expression [32]. Whether
miR-214 downregulation is involved in the up-regulation of
eNOS in this model used in our work remains to be studied.
Notably, the preceding studies indicate that NO inhibits
VSMC proliferation by preventing an increase in cell [Ca2+]i
[33], and Rg1 has been reported to inhibit Ca2+ inﬂux in the
neuronssuﬀeredfromhypoxic-ischemicinjury[34].Because
vasoconstrictor agonists and growth factors generally cause
an increase in cytosolic Ca2+ within seconds to minutes
[33], we detected the [Ca2+]i level of VSMCs at 3 minutes
after addition of PDGF-BB. Surprisingly, the result showed
that in our experimental conditions, Rg1 (administered
at 30 minutes before PDGF-BB addition) could cause a
further increase in the elevated [Ca2+]i induced by PDGF-
BB. Obviously, the increased [Ca2+]i could not be attributed
to NO formation, and might be the direct action of Rg1 to
Ca2+ inﬂux or Ca2+ release from the endoplasmic reticulum.
We conjectured that the NO formation-promoting eﬀect of
Rg1mightbenotstrongenoughtoreducethe[Ca2+]i levelof
VSMCsattheCa2+-detectiontime(3minutesafterPDGF-BB
addition), and the antiproliferative eﬀect of Rg1 via promot-
ing NO-formation perhaps occurred when larger amount
of eNOS expression had been restored. On the other hand,
some investigators reported that the Ca2+-increasing agents
includingCa2+ ionophoreA23187,ionomycin,cyclopiazonic
acid, and di-tert-butylhydroquinone had little eﬀect on
proliferation of VSMCs, and they thought that an increase
in [Ca2+]i per se does not appear to be important in
VSMC replication [35]. What is the relationship between the
Ca2+-increasing eﬀect of Rg1 and its VSMC proliferation-
inhibiting eﬀect remained to be studied.
It is concluded that one of the mechanisms for Rg1
inhibition on VSMC proliferation is related to the up-
regulation of eNOS mRNA and increases the formation of
NO and cGMP.
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